Role of proteomics in translational research in cervical cancer

Cervical cancer is one of the leading causes of cancer morbidity and mortality in women worldwide. More than 98% of cases are related to a human papillomavirus (HPV) infection. Infection with specific subtypes of HPV has been strongly implicated in cervical carcinogenesis. The identification and functional verification of host proteins associated with HPV E6 and E7 oncoproteins may provide useful information for understanding cervical carcinogenesis and the development of cervical cancer-specific markers. In addition, proteomic profiling of altered proteins by anticancer drugs on cervical cancer cells may contribute to providing the fundamental resources for investigation of disease-specific target proteins, elucidation of the novel mechanisms of action and development of new drugs. The advent of proteomics has provided the hope of discovering novel biological markers for use in the screening, early diagnosis and prediction of response to therapy. This review describes the studies where profiles of protein expression in cervical cancer have been generated.

[1]  E. Petricoin,et al.  Signal pathway profiling of prostate cancer using reverse phase protein arrays , 2003, Proteomics.

[2]  E. Diamandis.  Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. , 2004, Journal of the National Cancer Institute.

[3]  D. Hochstrasser,et al.  Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. , 1996, Biotechnology & genetic engineering reviews.

[4]  S. Patterson,et al.  Mass spectrometry and proteomics. , 2000, Physiological genomics.

[5]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[6]  K. Grankvist,et al.  Plasma prealbumin in women with epithelial ovarian carcinoma. , 1994, Gynecologic and obstetric investigation.

[7]  A. Görg,et al.  The current state of two‐dimensional electrophoresis with immobilized pH gradients , 2000, Electrophoresis.

[8]  H. Yanagi,et al.  Cytosolic Chaperonin Is Up-regulated during Cell Growth , 1999, The Journal of Biological Chemistry.

[9]  Minh N. H. Nguyen,et al.  The PDZ Ligand Domain of the Human Papillomavirus Type 16 E6 Protein Is Required for E6's Induction of Epithelial Hyperplasia In Vivo , 2003, Journal of Virology.

[10]  A. Laggner,et al.  Evaluation of coagulation markers for early diagnosis of acute coronary syndromes in the emergency room. , 2002, Clinical chemistry.

[11]  S. Mok,et al.  Protein profiling of cervical cancer by protein-biochips: proteomic scoring to discriminate cervical cancer from normal cervix. , 2004, Cancer letters.

[12]  K. Vousden,et al.  Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation , 1991, Cell.

[13]  Zhaodan Cao,et al.  TRAF6 is a signal transducer for interleukin-1 , 1996, Nature.

[14]  Y. Bourbonnais,et al.  Anti-inflammatory activity of neutrophil elastase inhibitors. , 2003, Current opinion in investigational drugs.

[15]  Pier Giorgio Righetti,et al.  A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431 , 2004, Proteomics.

[16]  E. Tokunaga,et al.  Diminished expression of ING1 mRNA and the correlation with p53 expression in breast cancers. , 2000, Cancer letters.

[17]  S. Howell,et al.  Regulation of HSP60 mRNA expression in a human ovarian carcinoma cell line , 2004, Cancer Chemotherapy and Pharmacology.

[18]  C. Thompson,et al.  Bax and Bak Independently Promote Cytochrome cRelease from Mitochondria* , 2002, The Journal of Biological Chemistry.

[19]  S. Namkoong,et al.  Functional inactivation of p73, a homolog of p53 tumor suppressor protein, by human papillomavirus E6 proteins , 2001, International journal of cancer.

[20]  D. Chan,et al.  Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. , 2002, Clinical chemistry.

[21]  G M Kasof,et al.  Livin, a Novel Inhibitor of Apoptosis Protein Family Member* , 2001, The Journal of Biological Chemistry.

[22]  K. Münger,et al.  Interactions of the human papillomavirus E7 protein with cell cycle regulators. , 1996, Seminars in cancer biology.

[23]  Y. Cheng,et al.  Metabolism and mechanism of action of 5-fluorouracil. , 1990, Pharmacology & therapeutics.

[24]  R. Paules,et al.  Inactivation of G2 checkpoint function and chromosomal destabilization are linked in human fibroblasts expressing human papillomavirus type 16 E6. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[25]  S. Korsmeyer,et al.  BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. , 2001, Molecular cell.

[26]  M Fujita,et al.  Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[27]  D. Ribatti,et al.  Docetaxel versus paclitaxel for antiangiogenesis. , 2002, Journal of hematotherapy & stem cell research.

[28]  William,et al.  Inactivation of G 2 Checkpoint Function and Chromosomal Destabilization Are Linked in Human Fibroblasts Expressing Human Papillomavirus Type 16 E 6 ’ , 2005 .

[29]  S. Weinberger,et al.  Recent advancements in surface‐enhanced laser desorption/ionization‐time of flight‐mass spectrometry , 2000, Electrophoresis.

[30]  O. Ogawa,et al.  Activation of caspase-3 in renal cell carcinoma cells by anthracyclines or 5-fluorouracil. , 2001, International journal of oncology.

[31]  O. Delattre,et al.  A key role of the hSNF5/INI1 tumour suppressor in the control of the G1-S transition of the cell cycle , 2002, Oncogene.

[32]  N. Holbrook,et al.  Requirement for ERK Activation in Cisplatin-induced Apoptosis* , 2000, The Journal of Biological Chemistry.

[33]  Arnold J. Levine,et al.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 , 1990, Cell.

[34]  P. Schellhammer,et al.  Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.

[35]  K. Münger,et al.  Association of the human papillomavirus type 16 E7 oncoprotein with the 600-kDa retinoblastoma protein-associated factor, p600. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[36]  F Lipari,et al.  Purification and biophysical characterization of a minimal functional domain and of an N-terminal Zn2+-binding fragment from the human papillomavirus type 16 E6 protein. , 2001, Biochemistry.

[37]  J. Yates,et al.  Large-scale analysis of the yeast proteome by multidimensional protein identification technology , 2001, Nature Biotechnology.

[38]  S. J. Kim,et al.  Physical status and expression of HPV genes in cervical cancers. , 1997, Gynecologic oncology.

[39]  Protein profiling and identification of modulators regulated by human papillomavirus 16 E7 oncogene in HaCaT keratinocytes by proteomics. , 2005, Gynecologic oncology.

[40]  Jong-Sup Park,et al.  Proteomic analysis of antiproliferative effects by treatment of 5-fluorouracil in cervical cancer cells. , 2004, DNA and cell biology.

[41]  Do-Young Yoon,et al.  Protein profiling and identification of modulators regulated by the E7 oncogene in the C33A cell line by proteomics and genomics , 2004, Proteomics.

[42]  E. Yim,et al.  Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. , 2005, Gynecologic oncology.

[43]  J. Nevins,et al.  Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Jong-Sup Park,et al.  Genomic and proteomic expression patterns in HPV-16 E6 gene transfected stable human carcinoma cell lines. , 2004, DNA and cell biology.

[45]  Jong-Sup Park,et al.  Inactivation of Interferon Regulatory Factor-1 Tumor Suppressor Protein by HPV E7 Oncoprotein , 2000, The Journal of Biological Chemistry.

[46]  C. Sawyers,et al.  Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation , 2002, Oncogene.

[47]  J. Choe,et al.  SWI/SNF Complex Interacts with Tumor Suppressor p53 and Is Necessary for the Activation of p53-mediated Transcription* , 2002, The Journal of Biological Chemistry.

[48]  Emanuel F Petricoin,et al.  Protein microarrays: meeting analytical challenges for clinical applications. , 2003, Cancer cell.

[49]  Ting-ting Chen,et al.  Cisplatin restores p53 function and enhances the radiosensitivity in HPV16 E6 containing SiHa cells , 2004, Journal of cellular biochemistry.

[50]  S. Lee,et al.  Interaction of human Ku70 with TRF2 , 2000, FEBS letters.

[51]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[52]  T. R. Broker,et al.  Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. , 1995, Genes & development.

[53]  Standing,et al.  A tandem quadrupole/time-of-flight mass spectrometer with a matrix-assisted laser desorption/ionization source: design and performance , 2000, Rapid communications in mass spectrometry : RCM.

[54]  N. McMillan,et al.  The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. , 1999, Virology.

[55]  Adam Z. Stieg,et al.  Mass Spectroscopy as a Discovery Tool for Identifying Serum Markers for Prostate Cancer , 2001 .

[56]  T. Jacks,et al.  The retinoblastoma gene family in differentiation and development , 1999, Oncogene.